Sirenia Capital Management LP Acquires 7.5% Stake in Corvus Pharmaceuticals via Warrants

On May 15, 2026, Sirenia Capital Management LP and Alex Silverstein filed a Schedule 13G disclosing a new 7.5% ownership stake in Corvus Pharmaceuticals, Inc. (CRVS). The reporting persons beneficially own 6,831,828 shares of Common Stock, which are issuable upon the exercise of warrants held by an investment fund and a managed account overseen by Sirenia. Alex Silverstein, as the managing member of Sirenia Capital Management GP LLC, shares voting and dispositive power over these securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The calculation of the ownership percentage is based on approximately 83,992,407 shares outstanding as of March 12, 2026, adjusted for the assumed exercise of the reported warrants. This filing establishes a significant position for Sirenia Capital Management in the biotechnology firm.